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Summary
Background In southeast Asia, antibiotic prescription in febrile patients attending primary care is common, and a 
probable contributor to the high burden of antimicrobial resistance. The objective of this trial was to explore whether 
C-reactive protein (CRP) testing at point of care could rationalise antibiotic prescription in primary care, comparing 
two proposed thresholds to classify CRP concentrations as low or high to guide antibiotic treatment.
Methods We did a multicentre, open-label, randomised, controlled trial in participants aged at least 1 year with a 
documented fever or a chief complaint of fever (regardless of previous antibiotic intake and comorbidities other than 
malignancies) recruited from six public primary care units in Thailand and three primary care clinics and one 
outpatient department in Myanmar. Individuals were randomly assigned using a computer-based randomisation 
system at a ratio of 1:1:1 to either the control group or one of two CRP testing groups, which used thresholds of 
20 mg/L (group A) or 40 mg/L CRP (group B) to guide antibiotic prescription. Health-care providers were masked to 
allocation between the two intervention groups but not to the control group. The primary outcome was the prescription 
of any antibiotic from day 0 to day 5 and the proportion of patients who were prescribed an antibiotic when CRP 
concentrations were above and below the 20 mg/L or 40 mg/L thresholds. The primary outcome was analysed in the 
intention-to-treat and per-protocol populations. The trial is registered with ClinicalTrials.gov, number NCT02758821, 
and is now completed.
Findings Between June 8, 2016, and Aug 25, 2017, we recruited 2410 patients, of whom 803 patients were randomly 
assigned to CRP group A, 800 to CRP group B, and 807 to the control group. 598 patients in CRP group A, 593 in CRP 
group B, and 767 in the control group had follow-up data for both day 5 and day 14 and had been prescribed antibiotics 
(or not) in accordance with test results (per-protocol population). During the trial, 318 (39%) of 807 patients in the 
control group were prescribed an antibiotic by day 5, compared with 290 (36%) of 803 patients in CRP group A and 
275 (34%) of 800 in CRP group B. The adjusted odds ratio (aOR) of 0·80 (95% CI 0·65–0·98) and risk difference of 
–5·0 percentage points (95% CI –9·7 to –0·3) between group B and the control group were significant, although 
lower than anticipated, whereas the reduction in prescribing in group A compared with the control group was not 
significant (aOR 0·86 [0·70–1·06]; risk difference –3·3 percentage points [–8·0 to 1·4]). Patients with high CRP 
concentrations in both intervention groups were more likely to be prescribed an antibiotic than in the control group 
(CRP ≥20 mg/L: group A vs control group, p<0·0001; CRP ≥40 mg/L: group B vs control group, p<0·0001), and those 
with low CRP concentrations were more likely to have an antibiotic withheld (CRP <20 mg/L: group A vs control 
group, p<0·0001; CRP <40 mg/L: group B vs control group, p<0·0001). 24 serious adverse events were recorded, 
consisting of 23 hospital admissions and one death, which occurred in CRP group A. Only one serious adverse event 
was thought to be possibly related to the study (a hospital admission in CRP group A).
Interpretation In febrile patients attending primary care, testing for CRP at point of care with a threshold of 40 mg/L 
resulted in a modest but significant reduction in antibiotic prescribing, with patients with high CRP being more 
likely to be prescribed an antibiotic, and no evidence of a difference in clinical outcomes. This study extends the 
evidence base from lower-income settings supporting the use of CRP tests to rationalise antibiotic use in primary 
care patients with an acute febrile illness. A key limitation of this study is the individual rather than cluster 
randomised study design which might have resulted in contamination between the study groups, reducing the effect 
size of the intervention.
Funding Wellcome Trust Institutional Strategic Support Fund grant (105605/Z/14/Z) and Foundation for Innovative 
New Diagnostics (FIND) funding from the Australian Government.
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Introduction 
Southeast Asia is a global hub of antimicrobial resistance, 
which is associated with high morbidity and mortality,1 
and is a probable exporter of antimicrobial resistance 
through dense travel and agricultural trade networks.2 
With an extensive population reach, primary care could 
be a major force in the fight against antimicrobial 
resistance; instead, primary care is a setting in which 
antibiotic prescription is widespread and poorly 
regulated.3 Challenges include high patient throughput, 
diagnostic uncertainty, patient expectations of treatment, 
and reluctance to refrain from prescribing when follow-
up is challenging.4−6 A situational analysis of antimicrobial 
resistance in southeast Asia reported that in Myanmar 
87% of patients with upper respiratory tract infections in 
primary care received an antibiotic, as did 43% of patients 
in Thailand. A review of 32 primary care centres in 
northern Thailand found that 47·6% of patients with a 
documented fever were prescribed antibiotics.7,8
Fever is a common reason for attending primary care 
facilities. Although malaria can be readily ruled out with 
rapid tests, the ubiquitous use of these tests as malaria 
declines implies that most febrile patients will have a 
negative test result. Health-care providers in primary 
care, however, have no means to diagnose other causes of 
acute fever, driving further inappropriate antibiotic 
prescrip tion.9 Concurrently, patients with potentially life-
threatening bacterial diseases such as scrub typhus and 
leptospirosis, which are widespread in southeast Asia, 
often receive no treatment or inappro priate antibiotics.10,11 
Ideally, pathogen-specific rapid tests would establish 
whether and which antibiotics are required at point of 
care, but use of these tests is unlikely to be feasible in the 
foreseeable future because of the small range of point-of-
care tests that are available, with many tests being unable 
to distinguish between invasive infection and past 
exposure. Furthermore, even well resourced research 
studies using laboratory reference tests and paired 
samples rarely identify a pathogenic agent in more than 
half of febrile patients.10−12
Point-of-care tests for host-response biomarkers offer 
an alternative to pathogen-specific testing, with the 
potential for ruling out the need for antibiotic treatment 
and reassuring health-care providers and patients when 
this treatment is less likely to be required. The need for 
simple tests to assist in prescribing decisions has been 
recognised globally,13 but few potential biomarkers have 
been evaluated across a broad range of settings and 
Research in context
Evidence before this study
Retrospective studies have found C-reactive protein (CRP) to be 
highly sensitive and moderately specific in the identification of 
bacterial infection in blood samples from febrile patients. One 
such study of over 1300 microbiologically confirmed infections 
in patients across southeast Asia found a sensitivity of 86% and 
a specificity of 67% for CRP at a threshold of 20 mg/L, with an 
area under the curve of the receiver operating characteristic of 
0·83 (95% CI 0·81–0·86). A Cochrane systematic review of six 
studies including more than 3000 patients in primary care who 
presented with acute respiratory infections in high-income 
settings concluded that CRP was an effective measure to reduce 
antibiotic prescription. Another systematic review of clinical 
trials of host biomarker testing for the identification of serious 
infections in children concluded that CRP tests could be 
diagnostically useful, but more evidence was needed on specific 
thresholds. A cluster randomised controlled trial from Belgium 
concluded that CRP testing should be targeted at children at risk 
of severe infections. Neither this study nor those in the 
systematic reviews originate in low-income and middle-income 
countries (LMICs) where the burden of infectious diseases is 
high and access to well trained clinicians can be low. We 
searched MEDLINE for studies published in English using the 
combination of “trial”, “fever” or “febrile”, and “C reactive 
protein” and identified two relevant trials from LMICs. We 
applied no date restriction to our search and our last search was 
Jan 20, 2018. In Tanzania, CRP testing was incorporated within 
a bundle of interventions that resulted in a large reduction in 
antibiotic prescribing in children attending outpatient clinics 
from a baseline of 94·9% to just 11·5%. In Vietnam, CRP testing 
alone in patients with acute respiratory tract infections reduced 
antibiotic prescribing from 78% in the control group to 64% in 
the intervention group.
Added value of this study
We extended the evaluation of CRP testing in southeast Asian 
primary care settings to all acutely febrile patients older than 
12 months. The study included two intervention groups with 
different CRP thresholds indicating the need for antibiotics. 
The findings suggest that only the higher threshold of 40 mg/L 
was associated with significant reductions in prescribing 
compared with the control group, although all three study 
groups had significantly lower antibiotic prescription than 
those documented in retrospective surveys before the trial. In 
both intervention groups, patients with elevated CRP were 
more likely to be prescribed an antibiotic than those in the 
control group, providin g an additional diagnostic safety layer 
that could be particularly important in settings where access to 
well trained clinicians is low.
Implications of all the available evidence
In primary care settings in southeast Asia where the prevalence 
of antibiotic prescription is high, CRP testing can be used to 
inform the management of patients with an acute fever and 
those with an acute respiratory tract infection.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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populations, and none has shown perfect diagnostic 
performance.14,15
C-reactive protein (CRP) is an acute-phase biomarker 
of inflammation. Although increases in CRP concen-
trations have a variety of causes,16 the utility of CRP in 
distinguishing between bacterial and viral infections has 
been shown in stored samples from febrile patients in 
southeast Asia across diverse settings and populations, 
including inpatients, outpatients, children, adults, and 
pregnant women.17,18 These studies concluded that CRP is 
highly sensitive and moderately specific in identifying 
bacterial infections. Although research and develop-
ment for better biomarkers continues, CRP testing is 
potentially a readily available means of improving 
prescribing decisions as a plethora of CRP point-of-care 
tests are commercially available,19 with some costing less 
than US$1·00.20 However, selecting a CRP test for use in 
routine care requires the identification of optimal 
thresholds to indicate the need for antibiotic treatment, 
for which scant evidence is available.
A clinical trial in Vietnamese patients with acute 
respiratory tract infections in primary care21 found that 
CRP testing with a threshold of 10 mg/L in children and 
20 mg/L in adults reduced antibiotic prescription from 
78% to 64% without altering the duration of symptoms. 
The objective of our clinical trial was to estimate the effect 
of CRP testing on antibiotic prescription in acutely febrile 
children and adults attending primary care in Thailand 
and Myanmar. Previous trials of CRP-guided antibiotic 
treatment used quantitative readers, which are unlikely to 
be available in many low-income and middle-income 
settings. In our trial, health-care providers were notified 
only as to whether CRP concentrations were low or high 
with respect to two proposed thresholds—20 mg/L and 
40 mg/L. Identifying an optimal threshold for CRP-guided 
antibiotic treatment could inform the choice of lateral flow 
devices for use in routine primary care settings.
Methods
Study design and participants 
This study was designed as a multicentre, open-label, 
randomised, controlled trial that compared CRP-guided 
antibiotic prescription in febrile patients with the 
standard prescribing practice. The design included 
two intervention groups with CRP thresholds of 20 mg/L 
and 40 mg/L to guide antibiotic prescription. These 
thresholds were selected on the basis of previous 
literature on CRP concentrations in febrile patients,22,23 
particularly studies from southeast Asia,17,18 including a 
study from Chiangrai, Thailand, that evaluated 20 mg/L 
and 40 mg/L CRP as candidate thresholds for the 
identification of bacterial infections (sensitivity of 92% 
for 20 mg/L and 86% for 40 mg/L).24
In Thailand, primary care units (PCUs) in Chiangrai 
were selected as study sites for patient recruitment, with 
the intention of including facilities with high patient 
turnover while ensuring diversity in terms of the rural or 
urban environment. Two PCUs were initially included, 
and four additional sites were later opened because of 
slow recruitment. In Myanmar, the study was done in 
three Medical Action Myanmar (MAM) clinics and in 
one adjacent hospital outpatient department located 
in the poorest township of Yangon (table 1).25 
In terms of policy environment and antimicrobial 
resistance awareness campaigns, Thailand has been 
notably active compared with other countries in the 
region,7 including through its Antibiotic Smart Use 
(ASU) programme, in place since 2007.26 The programme 
set a target prescription rate of 20% per month for 
respiratory infections and acute diarrhoea as part of the 
key performance indicators for PCUs; this target has 
been integrated in a pay-for-performance (P4P) policy of 
the National Health Security Office since 2009. In August, 
2016 (during the study), the National Strategic Plan on 
antimicrobial resistance 2017−21 was endorsed by the 
cabinet as Thailand’s first national strategy addressing 
antimicrobial resistance challenges, and the Ministry of 
Public Health (MOPH) adopted the ASU targets into its 
Service Plan Policy on Rational Drug Use (RDU).27 Unlike 
the previous P4P policy that provided financial incentives 
at the facility level, the RDU Service Plan incentivised 
higher-level stakeholders in the MOPH to exercise their 
authority in meeting the antibiotic prescription targets. 
To achieve this, the MOPH now relies on health 
Chiangrai, Thailand Hlaing Tha Yar, Myanmar
Sites Six public primary care units Three primary care clinics and one outpatient department 
(government hospital)
Location Rural and peri-urban settings within a 30 km radius of 
Chiangrai city centre
Slum areas and peri-urban townships on the west side of Yangon
Health-care provider Two to three registered nurses per site Two to five medical doctors per site
Access fees Universal health coverage for registered citizens* Free
Population Thai community, 15% ethnic minorities Mainly Burmese community
Investigations routinely available Finger-prick blood glucose test Rapid test for malaria
Malaria transmission 0–0·1 cases per 1000 population 0–0·1 cases per 1000 population
*THB30 (US$0·91) were previously charged per visit; this fee is now inconsistently applied.
Table 1: Trial sites 
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inspectors to guide and encourage hospitals and PCUs 
to reduce the unnecessary use of antibiotics. The 
antimicrobial-resistance policy environ ment in Myanmar 
is not well developed, with no relevant policies introduced 
between 2010 and 2015.7
In addition to the influence of the shifting policy 
environment, we anticipated a potential for observation 
bias due to the presence of research staff and a possible 
contamination effect on prescribing in the control group 
resulting from exposure to CRP test results in the 
intervention groups (ie, if healthcare providers observe 
low frequency of patients with high CRP in the 
interventions groups, this might affect their prescribing 
in patients in the control group). Therefore, to understand 
the prescribing practices in febrile patients in the trial 
sites before intervention, we did surveys to include 
retrospective data from January, 2015, to December, 2016, 
in Thailand, and from November, 2015, to April, 2016, 
in Myanmar. Further details on the data collection 
processes for the background surveys are presented in 
the appendix.
All participants in the trial were aged 1 year or older 
with a documented fever (defined as a tympanic 
temperature of >37·5°C according to WHO standards) or 
a chief complaint of fever (<14 days), regardless of 
previous antibiotic intake and comorbidities other than 
malignancies. The exclusion criteria were as follows: 
infants younger than 1 year; symptoms requiring hospital 
referral, defined as either impaired consciousness, 
inability to take oral medication, or convulsions; a 
positive malaria test; the main complaint being trauma 
or injury; suspicion of either tuberculosis, urinary tract 
infection, or local skin or dental abscess or infection; 
any symptom present for more than 14 days; any 
bleeding; and an inability to comply with the follow-up 
visit at day 5. A complete list of all inclusion and 
exclusion criteria can be found in the protocol summary 
on ClinicalTrials.gov. All participants (or parents or 
guardians in the case of children) provided written 
informed consent. The protocol, informed consent form, 
and case record forms were reviewed and approved by 
the Oxford Tropical Research Ethics Committee, the 
Mahidol University Faculty of Tropical Medicine Ethics 
Committee, and the Myanmar Department of Medical 
Research and Chiangrai Provincial Public Health Office 
Research Ethics Committees.
Study staff explained the trial to potential participants 
and took their written informed consent to join the study 
before any study-specific procedures were done. In the 
case of participants younger than 18 years, a parent or 
guardian was asked to sign and date the informed 
consent form (ICF) and the participant was asked to give 
consent or assent depending on their age and local 
practice. In the case of illiterate patients or parents or 
guardians, a witness was asked to sign the ICF to confirm 
that the participant gave informed verbal consent to 
participate.
Randomisation and masking 
Individuals were randomly assigned at a 1:1:1 ratio to either 
one of the two intervention groups or the control group and 
were stratified by country (Thailand and Myanmar) and age 
group (children and adults, with adulthood defined as age 
≥12 years). Computer-based individual randomisation was 
done at the Mahidol-Oxford Tropical Medicine Research 
Unit, Bangkok, Thailand by the trial statistician (MM) 
using the ralloc command in Stata version 14. Numbered, 
sealed, opaque envelopes containing the randomised study 
group were prepared by the central support team and 
opened sequentially on site by the study staff after patients 
were enrolled. Study groups consisted of intervention 
groups A and B, in which CRP was measured by study staff 
on site and the result was communicated to the health-care 
provider as low CRP or high CRP using cutoff thresholds 
of 20 mg/L (group A) or 40 mg/L (group B), and control 
group C, in which health-care providers were asked to 
manage febrile patients as per standard of care.
Health-care providers and patients were masked to 
allocation between the two intervention groups but by 
design were aware of allocation to the control group. 
Research staff could not be masked to patient allocation 
between all groups.
Procedures 
Before patient recruitment, the health-care providers 
were informed of the utility of CRP to help guide anti-
biotic prescription, while mitigating the threat of anti-
microbial resistance. The information was provided by 
the study investigators in the local language and dialect, 
on the basis of previous models developed for CRP-
testing-related training,28 and contextualised to the Thai 
and Myanmar settings. A refresher session was provided 
around the midpoint of study recruitment. Health-care 
providers were advised that for febrile patients with no 
clear danger signs and low CRP concentrations they 
should refrain from prescribing antibiotics, whereas for 
patients with high CRP the guidance was to consider 
prescribing antibiotics on the basis of their clinical 
judgment. The health-care providers were informed that 
the test was not of perfect accuracy in its identification of 
patients requiring antibiotic treatment.
Following randomisation, patients from the inter vention 
groups had a capillary blood sample analysed for CRP on 
site by the study staff who used a CRP reader (NycoCard II 
Reader, Axis Shield, Oslo, Norway). A brief educational 
video on antimicrobial resistance and CRP was shown to 
participants in the intervention groups with the intention 
of ensuring patients’ understanding of the test. The 
participants were then provided with a card specifying 
whether their CRP concentrations were high or low in 
relation to their intervention group and referred to the 
health-care provider. In the control group, a venous blood 
sample was collected by study staff, stored at 4°C, and 
retrospectively tested for CRP concentrations. All patients 
then proceeded to a routine medical examination by the 
For a summary of the protocol 
see https://clinicaltrials.gov/ct2/
show/NCT02758821
For the educational video on 
antimicrobial resistance and 
CRP see https://www.youtube.
com/watch?v=hJnxSwbqWOE&fe
ature=youtu.be
See Online for appendix
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primary-care health provider who decided whether an anti-
biotic was required. Demographic and clinical data were 
recorded by the study staff on a case report form (CRF).
All patients were followed up both at day 5 (allowable 
range 4−7 days) and day 14 (allowable range 12−16 days) 
after recruitment by face-to-face appointment with study 
staff. If patients were unable to attend a follow-up visit in 
person, a structured telephone interview was done 
instead. Patients in all three groups were tested for CRP 
at the second visit (day 5) on site by the study staff to help 
gauge clinical recovery, and health-care providers were 
informed if CRP concentrations were equal to or higher 
than 50 mg/L in children, and equal to or higher than 
100 mg/L in adults.
Patients received compensation for their time and 
travel expenses at enrolment and on each of the follow-
up visits if they reattended in person.
Outcomes 
The primary outcome was the proportion of patients who 
were prescribed any antibiotic at the facility from day 0 to 
day 5 (allowable range 4–7) in each intervention group in 
total, and the proportion of patients who were prescribed 
an antibiotic when CRP concentrations were above 
and below the 20 mg/L or 40 mg/L thresholds. The 
CRP reading was done in a central lab off-site for 
the control group and it was performed on site for 
the intervention groups. The data on prescribing were 
recorded independently on site and the outcome was 
assessed centrally. Secondary outcomes included the 
proportion of patients prescribed an antibiotic from day 0 
to day 14 at the health facility. Clinical outcomes included 
patient self-reported recovery at each follow-up visit, 
duration and severity of symptoms, frequency of un-
planned reconsultation within the 14 days of follow-up, 
temperature and CRP concentrations at day 5 as objective 
measures of clinical recovery, and occurrence of serious 
adverse events, defined as events requiring admission to 
hospital or death within 14 days of enrolment. Due to the 
extensive trial outputs, this manuscript reports the 
primary outcome and key secondary outcomes relating 
to antibiotic prescribing and clinical recovery. The other 
Figure 1: Trial profile
CRP=C-reactive protein.
807 allocated to control group
35 lost to follow-up
772 completed day 5 follow-up
711 face-to-face interview 
61 phone interview
803 allocated to CRP group A, 20 mg/L
35 lost to follow-up
4116 patients assessed for eligibility
2410 randomised
1706 ineligible
22 aged <1 year
109 no consent
106 bleeding
101 trauma
309 symptoms >14 days
100 referred to hospital
7 malaria
438 suspicion of tuberculosis
129 urinary tract infection
242 skin or dental abscess
15 neoplastic disease
432 were not able to comply with follow-up
768 completed day 5 follow-up
715 face-to-face interview 
53 phone interview
800 allocated to CRP group B, 40 mg/L
29 lost to follow-up
33 lost to follow-up 41 lost to follow-up 19 lost to follow-up
771 completed day 5 follow-up
726 face-to-face interview 
45 phone interview
774 completed day 14 follow-up
651 face-to-face interview 
123 phone interview
762 completed day 14 follow-up
662 face-to-face interview 
100 phone interview
781 completed day 14 follow-up
673 face-to-face interview 
108 phone interview
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secondary outcomes of the study—the correlation 
between CRP results and clinical outcomes on day 5 of 
follow-up, the impact of CRP testing on antibiotic 
consumption obtained elsewhere after the first 
consultation, the attitudes and satisfaction of health-
centre staff and patients towards the CRP test, the 
prevalence of key pathogens in febrile patients in these 
settings, and the ability of CRP to discriminate between 
viral and bacterial pathogens—will be reported 
elsewhere.
Statistical analysis
We expected CRP testing to reduce antibiotic pre-
scriptions by 25% from baseline, but with anticipated 
contamination between study groups, the sample size 
was increased to detect a reduction in antibiotic 
prescription by 20% independently for children and 
adults in each country. The sample size was adjusted 
further to account for multiple comparisons between the 
three study groups on the basis of Bonferroni’s correction. 
An adjusted significance level (type I error) of 0·017 was 
used to yield a 5% overall significance level for the three 
comparisons. Allowing for a projected 15% loss to follow-
up required 198 patients per study group, rounded to 
200, to give a total of 2400 patients (600 children and 
600 adults per country).
The trial was analysed by intention to treat and per 
protocol (appendix). The per-protocol analysis included 
patients for whom follow-up data were available on both 
day 5 and day 14, and to whom health-care providers 
prescribed antibiotics in accordance with test results; 
therefore, the effect size in the per-protocol analysis 
represents the potential effect of the tests under full 
compliance.
Differences in primary and secondary outcomes were 
analysed overall and in the four predefined subgroups 
of country and age category. Descriptive statistics for 
continuous variables with normal distribution used 
means and SD and medians with IQR for non-normally 
distributed continuous variables. Comparison between 
groups used t tests for normally distributed variables, 
the Mann-Whitney test for non-normally distributed 
variables, and χ² test for categorical variables.
Primary and secondary outcomes between each of the 
intervention groups and the control group were 
compared using a logistic regression model; health 
facilities were considered to have a random effect on the 
primary outcome.
The difference in the number of prescriptions of 
various broad-spectrum antibiotics was also compared, 
including ceftriaxone, cefixime, ciprofloxacin, levo-
floxacin, azithromycin, and amoxicillin with clavulanic 
acid. The exhaustive list of antibiotics prescribed at the 
facilities is provided in the appendix. This analysis was 
not prespecified in the study protocol.
We generated Kaplan-Meier curves to visualise 
time to clinical recovery on the basis of the patient 
declaration, with a corresponding p value using a log-
rank test for survival curves. We used a Cox regression 
model to quantify the difference in clinical outcomes 
Control group CRP group A CRP group B
Aged <12 years 
(n=402)
Aged ≥12 years 
(n=405)
Aged <12 years 
(n=400)
Aged ≥12 years 
(n=403)
Aged <12 years 
(n=399)
Aged ≥12 years 
(n=401)
Demographic characteristics
Sex
Male 204 (51%) 159 (39%) 209 (52%) 156 (39%) 204 (51%) 174 (43%)
Female 198 (49%) 246 (61%) 191 (48%) 247 (61%) 195 (49%) 227 (57%)
Age, median (IQR), years 4 (2–7) 33 (22–52) 4 (2–7) 35 (20–53) 4 (2–7) 34 (21–51)
≥30 min to reach the facility 100 (25%) 66 (16%) 100 (25%) 69 (17%) 98 (25%) 81 (20%)
Presence of comorbidity* 15 (4%) 112 (28%) 16 (4%) 100 (25%) 20 (5%) 88 (22%)
Symptoms onset, median (IQR), days 2 (1–3) 3 (2–4) 2 (1–3) 3 (2–4) 2 (1–3) 3 (2–4)
Self-reported antibiotic intake 16 (4%) 25 (6%) 20 (5%) 17 (4%) 22 (6%) 29 (7%)
Clinical characteristics and self-reported symptoms
Documented fever (>37·5ºC) 200 (50%) 155 (38%) 203 (51%) 143 (35·5%) 223 (56%) 148 (37%)
Neurological symptoms† 62 (15%) 148 (37%) 39 (10%) 156 (39%) 40 (10%) 155 (39%)
Respiratory symptoms‡ 326 (81%) 323 (80%) 315 (79%) 315 (78%) 327 (82%) 299 (75%)
Gastrointestinal tract symptoms§ 104 (26%) 95 (23%) 124 (31%) 83 (21%) 109 (27%) 68 (17%)
Other symptoms¶ 9 (2%) 25 (6%) 41 (10%) 37 (9%) 30 (8%) 43 (11%)
Data are number (%) or median (IQR). CRP=C-reactive protein. *Comorbidities included HIV infection, chronic hepatitis B or C infection, cirrhosis, diabetes, asthma, anaemia, chronic obstructive pulmonary 
disease, gastritis, congenital heart or kidney disease, alcoholism, dyslipidaemia, glucose-6-phosphate dehydrogenase deficiency, hypertension, rheumatic heart disease, thalassaemia, or thyroid disease. 
†Neurological symptoms include headache, confusion, dizziness, or hearing loss. ‡Respiratory symptoms include sore throat, dyspnoea, chest pain, runny nose, or cough. §Gastrointestinal symptoms include 
nausea, vomiting, diarrhoea, or abdominal pain. ¶Other symptoms declared were defined by the presence of fever alone or symptoms other than those present in neurological, respiratory, or gastrointestinal 
symptoms. Common symptoms in this group included myalgia, arthralgia, jaundice, tiredness, chills, sweating, weight loss, skin eruption, dysuria, or eye redness. 
Table 2: Day 0 characteristics comparing control group, group A (20 mg/L CRP threshold), and group B (40 mg/L CRP threshold)  
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between inter vention and control groups calculating 
the adjusted hazard ratios (HRs), with age stratum and 
country as fixed effects and health-care centres as a 
Gaussian random effect. The 95% CIs have been 
provided where appropriate. Data analyses were done 
with Stata version 15. The Clinical Trial Support Group 
at the Mahidol Oxford Tropical Medicine Research Unit 
did two monitoring visits to each site to ensure the 
integrity of the data; the first visit took place after 
200 children and adults were enrolled in each country, 
and a second at the end of the study recruitment. This 
trial is registered with ClinicalTrials.gov, number 
NCT02758821.
Role of the funding source
The funders had no role in study design, data collection, 
data interpretation, or writing of the manuscript. The 
corresponding author (YL) had full access to all the data 
in the study and had the final responsibility to submit for 
publication.
Results 
A total of 4116 patients were assessed for eligibility, of 
whom 2410 children and adults with a documented fever 
or a history of fever were prospectively recruited between 
June 8, 2016, and Aug 25, 2017, across ten facilities 
(figure 1). 803 patients were randomly assigned to CRP 
group A, 800 to CRP group B, and 807 to the control 
group (the intention-to-treat population). 598 patients in 
CRP group A, 593 in CRP group B, and 767 in the control 
group had follow-up data for both day 5 and day 14 and 
had been prescribed antibiotics in accordance with test 
results, so were included in the per-protocol population. 
Patient characteristics in the control group and the two 
intervention groups were similar at day 0 (table 2). 
Patients attended the facilities within a median of 
2·5 days (IQR 1−4) after onset of symptoms. Clinically, 
respiratory symptoms were the most common presen-
tation, followed by gastro intestinal and neurological 
symptoms (stratified results per country and age category 
are presented in the appendix).
The retrospective background surveys in the six Thai 
sites (6993 patients in total) showed that between 
260 (29%) of 894 patients and 1406 (72%) of 1959 patients 
with a history of fever or a documented fever were 
prescribed antibiotics (figure 2). In patients with a 
documented fever, between 123 (37%) of 330 patients and 
453 (87%) of 518 patients in each of the sites were 
prescribed an antibiotic; these proportions were largely 
unchanged in the 2 years preceding the study as was 
generally the case in a review of prescribing practices in 
all PCUs in the same district.8 Among the four Myanmar 
sites (32 345 patients in total), only the Hlaing Tha Yar 
government hospital outpatient department had patient 
records that included febrile status and antibiotic 
prescription, in which 173 (69%) of 252 patients with a 
documented fever were prescribed an antibiotic. In the 
three MAM clinics, data were only available on the total 
number of non-routine visits (ie, excluding patients 
attending the clinic for HIV care, tuberculosis care, 
antenatal appointments, and family planning, as well as 
malnourished children), without a record of febrile 
status, and only the overall number of antibiotics 
prescribed during the corresponding period was known. 
Together, the pooled absolute numbers indicate that 
approximately 41% of non-routine clinic attendees 
received an antibiotic.
In the intention-to-treat population, we observed a 
significant difference in the trial primary outcome of 
antibiotic prescription from day 0 up to day 5 between the 
control group (318 [39%] of 807) and patients in group B 
(275 [34%] of 800), with a risk difference of –5·0 percentage 
points (95% CI –9·7 to –0·3) and an adjusted odds ratio 
(aOR) of 0·80 (95% CI 0·65 to 0·98; table 3). In group A, 
Figure 2: Background antibiotic prescription in Thailand and Myanmar
OPD=outpatient department. *Estimated prescriptions in patients for whom clinical data on febrile status were available. †Estimated prescriptions in all patients on 
non-routine visits (febrile status unknown).
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290 (36%) of 803 patients were prescribed an antibiotic 
from day 0 to day 5, a non-significant difference compared 
with control group (risk difference –3·3 percentage 
points, 95% CI –8·0 to 1·4; aOR 0·86, 95% CI 0·70 to 
1·06). The per-protocol analysis (appendix) showed a 
–20·4 percentage point difference (95% CI –25 to –15·7) 
in antibiotic prescription for the primary outcome in 
group B compared with the control group (aOR 0·35, 
95% CI 0·27 to 0·45) and a –12·3 percentage point 
difference (–17·3 to –7·4) in group A compared with the 
control group (aOR 0·56, 0·44 to 0·71).
The trial primary outcome also included antibiotic 
prescription in relation to the CRP thresholds, with a 
higher proportion of patients with elevated CRP concen-
trations being prescribed an antibiotic in the intervention 
groups than in the control group (CRP ≥20 mg/L: 
153 [74%] of 206 patients in group A vs 103 [48%] of 214 in 
the control group, p<0·0001; CRP ≥40 mg/L: 92 [78%] of 
118 patients in group B vs 51 [48%] of 107 in the control 
group, p<0·0001; figure 3). Conversely, in patients with 
low CRP concentrations, antibiotic prescription was 
lower in the intervention groups than in the control 
group (CRP <20 mg/L: 119 [20%] of 595 patients in group 
A vs 134 [30%] of 445 in the control group, p<0·0001; 
CRP <40 mg/L: 153 [22%] of 682 patients in group B vs 
186 [34%] of 552 in the control group, p<0·0001). 
Considering a threshold of 20 mg/L CRP as indicative of 
requiring antibiotics, 414 (63%) of 659 patients in the 
control group had an antibiotic correctly prescribed or 
Control group CRP group A Risk difference (95% CI) aOR* (95% CI) CRP group B Risk difference (95% CI) aOR* (95% CI)
All age groups in Thailand and Myanmar
Number of participants 807 803 800
On day 0 297 (36·8%) 269 (33·5%) –3·3 (–8·0 to 1·4) 0·86 (0·70 to 1·06) 245 (30·6%) –6·2 (–10·8 to –1·6) 0·75 (0·60 to 0·92)
Between day 0 and day 5 318 (39·4%) 290 (36·1%) –3·3 (–8·0 to 1·4) 0·86 (0·70 to 1·06) 275 (34·4%) –5·0 (–9·7 to –0·3) 0·80 (0·65 to 0·98)
Between day 0 and day 14 323 (40·0%) 292 (36·4%) –3·7 (–8·4 to 1·1) 0·85 (0·69 to 1·04) 279 (34·9%) –5·2 (–10·0 to –0·4) 0·79 (0·64 to 0·98)
Patients aged <12 years in Thailand 
Number of participants 195 194 193
On day 0 64 (32·8%) 56 (28·9%) –4·0 (–13·1 to 5·2) 0·83 (0·53 to 1·28) 49 (25·4%) –7·4 (–16·4 to 1·6) 0·68 (0·43 to 1·08)
Between day 0 and day 5 68 (34·9%) 61 (31·4%) –3·4 (–12·8 to 5·9) 0·85 (0·55 to 1·31) 52 (26·9%) –7·9 (–17·1 to 1·2) 0·68 (0·43 to 1·06)
Between day 0 and day 14 69 (35·4%) 61 (31·4%) –3·9 (–13·3 to 5·4) 0·83 (0·54 to 1·28) 52 (26·9%) –8·4 (–17·6 to 0·7) 0·66 (0·42 to 1·03)
Patients aged ≥12 years in Thailand 
Number of participants 201 200 199
On day 0 63 (31·3%) 57 (28·5%) –2·8 (–11·8 to 6·1) 0·86 (0·56 to 1·34) 65 (32·7%) 1·3 (–7·8 to 10·5) 1·06 (0·69 to 1·63)
Between day 0 and day 5 64 (31·8%) 60 (30·0%) –1·8 (–10·9 to 7·2) 0·91 (0·59 to 1·40) 68 (34·2%) 2·3 (–6·9 to 11·5) 1·12 (0·73 to 1·71)
Between day 0 and day 14 64 (31·8%) 60 (30·0%) –1·8 (–10·9 to 7·2) 0·91 (0·59 to 1·40) 69 (34·7%) 2·8 (–6·4 to 12·1) 1·14 (0·74 to 1·75)
Patients aged <12 years in Myanmar 
Number of participants 207 206 206
On day 0 78 (37·7%) 77 (37·4%) –0·3 (–9·6 to 9·0) 0·99 (0·66 to 1·48) 65 (31·6%) –6·1 (–15·3 to 3·0) 0·76 (0·50 to 1·15)
Between day 0 and day 5 87 (42·0%) 84 (40·8%) –1·3 (–10·8 to 8·3) 0·95 (0·64 to 1·41) 79 (38·4%) –3·7 (–13·1 to 5·8) 0·86 (0·57 to 1·29)
Between day 0 and day 14 88 (42·5%) 86 (41·8%) –0·8 (–10·3 to 8·8) 0·97 (0·66 to 1·44) 82 (39·8%) –2·7 (–12·2 to 6·8) 0·90 (0·60 to 1·34)
Patients aged ≥12 years in Myanmar 
Number of participants 204 203 202
On day 0 92 (45·1%) 79 (38·9%) –6·2 (–15·8 to 3·4) 0·78 (0·52 to 1·15) 66 (32·7%) –12·4 (–21·8 to –3·0) 0·58 (0·38 to 0·87)
Between day 0 and day 5 99 (48·5%) 85 (41·9%) –6·7 (–16·3 to 2·3) 0·76 (0·52 to 1·13) 76 (37·6%) –10·9 (–20·5 to –1·3) 0·63 (0·42 to 0·94)
Between day 0 and day 14 102 (50·0%) 85 (41·9%) –8·1 (–17·8 to 1·5) 0·72 (0·49 to 1·07) 76 (37·6%) –12·4 (–22·0 to –2·8) 0·59 (0·40 to 0·89)
The prescription of antibiotics from day 0 to day 5 is the primary outcome. Unadjusted odds ratios are presented in the appendix. Data are number or number (%) unless otherwise stated. aOR=adjusted odds 
ratio. CRP=C-reactive protein. *aORs were adjusted by site as a random effect.
Table 3: Antibiotic prescription in the control group, group A (20 mg/L CRP threshold), and group B (40 mg/L CRP threshold) 
Figure 3: Antibiotic prescription on day 0 in relation to the CRP thresholds in each of the intervention groups 
for all age categories and countries
Error bars represent 95% CI. CRP=C-reactive protein.
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withheld, as compared with 632 (79%) of 801 in group A. 
Similarly, assuming a threshold of 40 mg/L as indicative 
of the need for an antibiotic, 417 (63%) of 659 in the 
control group had an antibiotic appropriately prescribed 
or withheld, as com pared with 621 (78%) of 800 in 
group B. Therefore, compliance with the test result was 
similarly high in the two intervention groups.
The risk difference in prescription in the subgroup 
of patients presenting with a documented fever was 
–7·5 percentage points (95% CI –14·7 to –0·3) in group B 
compared with the control group, and –3·7 percentage 
points (–11·0 to 3·7) in group A compared with the 
control group (table 4). Patients presenting with a 
respiratory syndrome in both intervention groups 
showed a significant reduction in antibiotic prescription, 
but did not show a significant reduction in the subgroup 
of patients with a neurological syndrome was observed. 
For patients with gastrointestinal symptoms, we did not 
observe a significant increase in prescription in the 
intervention groups compared with the control group.
Considering the follow-up period between day 0 and 
day 14, antibiotic prescription was –3·7 percentage points 
(95% CI –8·4 to 1·1) in group A, and –5·2 percentage 
points (95% CI –10·0 to –0·4) in group B, compared with 
the control group (table 3).
A post-hoc analysis showed that the prescription of 
broad-spectrum antibiotics (appendix) was lower at 
enrolment and throughout the follow-up visits in group 
B than in the control group (aOR 0·44, 95% CI 0·26–0·72 
at day 0; aOR 0·79, 95% CI 0·64–0·97 from day 0 to day 5; 
and aOR 0·79, 95% CI 0·64–0·98 from day 0 to day 14), 
whereas this reduction was only significant on day 0 in 
group A (aOR 0·60, 95% CI 0·38–0·96). 
We observed no differences in the prevalence of 
recovery as defined by patient declaration at day 5 or day 
14 of follow-up between the study groups, with 495 
(65%) of 764 at day 5 and 718 (94%) of 760 at day 14 in 
the 20 mg/L CRP group reporting recovery compared 
with 488 (63%) of 769 at day 5 and 733 (94%) of 779 at 
day 14 in the 40 mg/L CRP group, and 491 (64%) of 767 
at day 5 and 738 (96%) of 772 at day 14 in the control 
group (appendix). We present a comparison of the time-
to-event curves for recovery between groups A and B 
and the control group (figure 4). The corresponding log-
rank test and HRs in group A and group B were non-
significant. Similarly, no differences were found in 
these outcomes in the per-protocol analysis (appendix).
In cases of persistent illness at day 5 and day 14 of 
follow-up, the median symptom severity score corre-
sponded to the mildest grade (ie, a severity score of 1 in a 
scale ranging from 1 to 4) and did not differ across 
the groups (appendix). The proportion of patients who 
attended unscheduled visits was 16 (2%) of 807 in the 
control group, 13 (2%) of 803 in group A, and 22 (3%) of 
800 in group B with no significant difference 
between groups. CRP on day 5 was sufficiently elevated 
above the predefined threshold to notify health-care 
providers (50 mg/L in children and 100 mg/L in adults) in 
Control group 
(n=807)
CRP group A 
(n=803)
Risk difference 
(95% CI)
aOR* 
(95% CI)
CRP group B 
(n=800)
Risk difference 
(95% CI)
aOR* 
(95% CI)
Neurological presentation
Number of participants 210 195 ·· ·· 195 ·· ··
On day 0 83 (40%) 71 (36%) –3·1% (–12·6 to 6·3) 0·85 (0·56 to 1·29) 65 (33%) –6·2% (–15·6 to 3·2) 0·71 (0·46 to 1·10)
Between day 0 and day 5 90 (43%) 78 (40%) –2·9% (–12·5 to 6·7) 0·87 (0·58 to 1·31) 69 (35%) –7·5% (–17·0 to 2·0) 0·68 (0·45 to 1·05)
Between day 0 and day 14 92 (44%) 78 (40%) –3·8% (–13·4 to 5·8) 0·84 (0·55 to 1·26) 69 (35%) –8·4% (–17·9 to 1·1) 0·65 (0·43 to 1·00)
Respiratory presentation
Number of participants 649 630 ·· ·· 626 ·· ··
On day 0 263 (41%) 218 (35%) –5·9% (–11·2 to –0·6) 0·79 (0·62 to 0·99) 192 (31%) –9·9% (–15·1 to –4·6) 0·63 (0·50 to 0·81)
Between day 0 and day 5 281 (43%) 237 (38%) –5·7% (–11·1 to –0·3) 0·80 (0·63 to 1·00) 221 (35 %) –8·0% (–13·3 to –2·7) 0·70 (0·55 to 0·89)
Between day 0 and day 14 284 (44%) 238 (38%) –6·0% (–11·4 to –0·6) 0·79 (0·62 to 0·99) 225 (36%) –7·8% (–13·2 to –2·5) 0·71 (0·56 to 0·90)
Gastrointestinal presentation 
Number of participants 199 207 ·· ·· 177 ·· ··
On day 0 65 (33%) 75 (36%) 3·6% (–5·7 to 12·8) 1·17 (0·78 to 1·77) 63 (36%) 2·9% (–6·7 to 12·5) 1·16 (0·75 to 1·80)
Between day 0 and day 5 74 (37%) 82 (40%) 2·4% (–7·0 to 11·9) 1·11 (0·74 to 1·66) 67 (38%) 0·6% (–9·1 to 10·5) 1·04 (0·68 to 1·60)
Between day 0 and day 14 74 (37%) 83 (40%) 2·9% (–6·6 to 12·4) 1·13 (0·76 to 1·69) 67 (38%) 0·7% (–1·1 to 10·5) 1·04 (0·68 to 1·60)
Documented fever 
Number of participants 355 346 ·· ·· 371 ·· ··
On day 0 165 (47%) 148 (41%) –3·7% (–11·1 to 3·7) 0·85 (0·63 to 1·15) 141 (38%) –8·5% (–15·8 to –1·3) 0·66 (0·49 to 0·90)
Between day 0 and day 5 173 (49%) 156 (45%) –3·7% (–11·0 to 3·7) 0·85 (0·63 to 1·15) 153 (41%) –7·5% (–14·7 to –0·3) 0·71 (0·52 to 0·96)
Between day 0 and day 14 175 (49%) 157 (45%) –3·9% (–11·3 to 3·5) 0·84 (0·62 to 1·14) 154 (41%) –7·8% (–15·0 to –0·6) 0·70 (0·51 to 0·95)
Data are number or number (%) unless otherwise stated. The prescription of antibiotics from day 0 to day 5 is the primary outcome. aOR=adjusted odds ratio. CRP=C-reactive protein. *aORs were adjusted by site 
as a random effect.
Table 4: Subgroup analysis for antibiotic prescription
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eight (1%) of 706 patients in the control group, eight (1%) 
of 706 in CRP group A, and six (1%) of 726 in CRP group 
B with no significant difference between study groups. 
74 (3%) of 2150 patients had a tympanic temperature of 
more than 37·5°C on day 5 and 31 (2%) of 1951 on day 14 
with no significant differences between the study groups. 
Further details on clinical outcomes by age and country 
are presented in the appendix. 
Among the 2410 study participants, 24 severe adverse 
events occurred (23 hospital admissions and one death), 
with ten (1%) severe adverse events in group A, 11 (1%) in 
group B, and three (<1%) in the control group (p=0·064 
for group A and p=0·043 for group B compared with the 
control group). Among these 24 severe adverse events, 23 
were classified as being not related to the study (nine in 
group A, 11 in group B, and three in the control group), 
and one was classified as being possibly related, 
occurring in a woman aged 25 years who had an 
abdominal complaint and fever with low CRP (randomly 
assigned to group A), initially diagnosed by the attending 
health-care provider as a hypersensitivity reaction, and 
no antibiotic was prescribed. During admission the 
woman was diagnosed with mesenteric lympha denitis, 
and was prescribed antibiotics and discharged alive. No 
microbiological investigations were done at the hospital. 
One death occurred during the study, which was that of a 
man aged 78 years who was randomly assigned to group 
A and had chronic obstructive pulmonary disease and 
heart disease. The man’s CRP concentration was high, 
and antibiotics were prescribed on day 0; this severe 
adverse event was classified as not related to the study.
Discussion 
In this trial we have shown that, in primary care in 
southeast Asia, CRP testing with a threshold of 40 mg/L 
reduced antibiotic prescription in patients with a fever 
with no evidence of a difference in clinical recovery. 
Reductions in prescription were greater in patients with 
a documented fever, in those with respiratory presen-
tation, and for broad-spectrum antibiotics. In addition to 
reducing antibiotic prescription, patients in the inter-
vention groups with high CRP concentrations were more 
likely to be prescribed an antibiotic and those with low 
CRP concen trations were more likely to have antibiotics 
withheld than patients in the control group. These effects 
were more pronounced within group B, in which a 
higher threshold of 40 mg/L was used, whereas the 
differences between group A and the control group were 
of lesser magnitude and mostly not of statistical 
significance.
The effect size was smaller than anticipated when 
comparing the intervention and control groups but the 
difference in the proportion of patients who were 
prescribed antibiotics seemed to be much larger when 
comparing our trial data with our retrospective 2015–16 
antibiotic prescription data; whether these reductions in 
prescribing, small or large, can have a real effect on 
mitigating drug pressure and the development of 
antimicrobial resistance is difficult to establish. With the 
majority of human antibiotic consumption occurring in 
the community and in patients with fevers and respiratory 
illness in particular, even small reductions in prescription 
could imply a large alleviation of drug pressure. Further 
modelling and cost-effectiveness analyses are required to 
explore whether these reductions and the cost of achieving 
them are warranted from an economic and global health 
perspective. A modelling analysis conservatively estimated 
that in the Thai context the economic costs of antimicrobial 
resistance per course of broad-spectrum penicillins 
(widely used in this study) was approximately $10. A 
reduction of just 10 percentage points from baseline with 
the use of a CRP test costing $1 could therefore be 
considered cost beneficial from a societal perspective.29
The risk of serious bacterial infection in patients in 
primary care without clear clinical danger signs is low, 
Figure 4: Kaplan-Meier curves of symptom duration in the control group 
versus group A (20 mg/L) and group B (40 mg/L)
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and the majority of patients in the trial had low CRP 
concentrations on day 0 (<20 mg/L in 72% of patients 
and <40 mg/L in 86%; appendix). As CRP is known to be 
of high sensitivity but only moderate specificity in the 
detection of bacterial infections, the higher threshold of 
40 mg/L is likely to be appropriate for these settings, and 
stricter adherence to test results at this threshold would 
generate larger reductions in prescribing, as shown in 
the per-protocol analysis (>20% reduction for the primary 
outcome between group B and the control group; 
appendix). This reduction in prescribing might be 
achieved in scale-up programmes driven by local health 
authorities supported by high-level policy change. 
Integrating CRP testing into clinical guidelines could 
also enhance prescribers’ confidence, as might electronic 
user-friendly algorithms that strengthen the consistency 
of fever management.30 Clinical and communication 
skills training could also enhance compliance with 
these algorithms.31
A systematic review of studies on biomarker testing in 
febrile children in emergency departments, all in high-
income settings, concluded that CRP testing could be 
diagnostically useful, recommending a low threshold of 
5 mg/L to rule out serious infection and a threshold of 
80 mg/L to suggest the presence of serious infection.32 A 
cluster randomised trial in Belgium concluded that CRP 
testing in primary care should be targeted at children at 
high risk of severe infection after clinical assess ment.33 
This targeting could also avoid medical isation of minor 
ailments. A multicountry European study showed 
enhanced pneumonia prediction in patients in primary 
care presenting with acute cough when CRP testing was 
added to a clinical algorithm based on symptoms alone.34 
This risk stratification relied on the availability of 
experienced clinicians. In Thailand, which has a well-
developed public health sector, such strategies could 
be relevant, with adequate supervision of health-care 
providers’ clinical skills combined with clear referral and 
follow-up systems to ensure patient safety. The low 
number of prescriptions in the Thai control group 
suggests that reductions in prescribing could be attained 
with better training, supervision, or financial incentives, 
with CRP testing offering modest additional gains.
The evidence base for the evaluation of the effect of 
CRP-guided treatment from lower-income settings is 
small, and, because of particular comorbidities and 
pathogen exposure in lower-income countries in the 
tropics, data from high-income (non-tropical) settings 
are not easily comparable. A Tanzanian-based clinical 
trial on fever management showed that a host of 
interventions including CRP and procalcitonin tests, 
pulse oximetry, haemoglobin tests, and an electronic 
patient management algorithm, were able in combination 
to reduce prescribing from 95% to approximately 10% of 
patients.30 The costs and benefits of implementing a 
more comprehensive bundle of interventions need to be 
weighed against the lower costs and benefits of CRP 
testing alone. A trial using only CRP tests in acute 
respiratory tract infections in primary care in Vietnam 
reported a 20% reduction in prescribing on first 
attendance.21
Data for the retrospective survey in Thailand were 
obtained from a search of routinely collected electronic 
medical records, making the verification of the data 
challenging; however, CRF data from a subsample of 
patients included in this retrospective survey were 
compared with their respective routine medical records 
and were found to be consistent.8 The retrospectively 
collected 2015–16 antibiotic prescription data for the 
MAM sites did not include patients’ febrile status and 
only had the total number of prescriptions in the 
corresponding months, therefore our retrospectively 
collected prescription data are likely to underestimate the 
actual proportion of patients with a suspected infection 
who were prescribed an antibiotic. Despite these 
limitations, the retrospective surveys indicate much 
higher prescription rates than those observed in the 
research environment.
The primary outcome of the study, antibiotic 
prescription in response to CRP testing, is behavioural 
rather than biological, and therefore results need careful 
interpretation that considers contextual factors such as 
the broader policy environment and study design biases. 
In Thailand, reductions in prescribing were probably 
driven by policy changes implemented during the study 
period. Although our study adopted a mixed-methods 
approach that included social research components 
to better understand these contextual factors,35 dis-
entangling and quantifying their relative contribution 
is challenging. The addition of a diagnostic tool did, 
however, enable further reductions in prescribing, 
supporting a multifaceted approach.
The reduction in prescribing in all study groups could 
also be explained by the Hawthorne effect because of the 
presence of research staff on site who were carrying out 
the CRP tests and monitoring prescribing. Prescribing in 
the control group might also have been affected by 
contamination (because of recognition that most patients 
have low CRP concentrations and do not require an 
antibiotic), therefore underestimating the effect that CRP 
testing could have in a routine care environment. The 
ideal study design would therefore have been a cluster 
randomised trial without the presence of research staff 
on site and with the tests being performed by routine 
health-care providers.
Our study was powered to detect a difference in 
antibiotic prescription, rather than clinical outcomes. 
The reason we chose this endpoint was that CRP is 
already widely used in hospital settings in the 
management of febrile patients32 and has been shown to 
be highly sensitive in detecting bacterial infections in the 
region.18 In the context of primary care and with the 
exclusion of patients presenting with clear danger signs, 
we expected very few severe outcomes, as was indeed the 
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case. Although powering the study to detect differences 
in such rare events would not be feasible, the study 
recruited more than 2400 patients with high follow-up 
and no evidence of a difference between the groups was 
detected in the extensive measures of clinical outcome. 
Furthermore, in our study CRP tests were provided as an 
aid to health-care providers’ clinical judgment, with only 
soft recommendations on how the tests could inform 
their prescribing decisions.
CRP testing in a southeast Asian primary care setting 
has previously been shown to reduce antibiotic pre-
scribing in patients with respiratory tract infection and 
our trial extends this evidence base to those with a fever. 
Together, these patients represent the majority of acute 
primary care attendees. The fact that the proportion of 
patients in the control group who were prescribed an 
antibiotic seemed to be lower than our retrospectively 
collected data on antibiotic prescribing in the region 
indicates that substantial progress is attainable through 
other mechanisms, with CRP testing using a threshold of 
40 mg/L bringing a modest incremental effect. These 
findings correspond with previous studies recom-
mending a restricted use of CRP tests in high-risk groups, 
including children with high fever. This restricted use 
might well be viable in facilities staffed by experienced 
clinicians and where patient follow-up is feasible. In 
more peripheral settings, with minimally trained health-
care providers and where follow-up of patients is a 
challenge, testing all febrile patients could provide an 
additional safety net, ensuring that patients requiring 
treatment are identified as such. In these settings, low-
cost lateral flow devices are most likely to be relevant, for 
which we provide further evidence on the optimal 
threshold. Introduction of the tests should be planned in 
consideration of the local policy environment and 
accompanied by training for health-care providers and 
education for patients on the ability of CRP testing to 
identify when antibiotic treatment is required, and the 
need for better targeting of antibiotics in the fight against 
antimicrobial resistance.
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